Open AccessRole of antiarrhythmic drugs in patients with implantable cardioverter defibrillators
Author(s) -
Hugo Van Herendael,
Arnold Pintér,
K. Ahmad,
Victoria Korley,
Iqwal Mangat,
Paul Dorian
Publication year - 2010
Publication title -
ep europace
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 102
eISSN - 1532-2092
pISSN - 1099-5129
DOI - 10.1093/europace/euq073
Subject(s) - medicine , implantable cardioverter defibrillator , cardiology , intensive care medicine , drug , pharmacology
The transvenous implantable cardioverter defibrillator (ICD) has emerged as the primary therapy for patients at high risk of life-threatening ventricular arrhythmias. A high number of ICD recipients will require subsequent adjunctive treatment with antiarrhythmic drugs (AADs). This review provides an overview of potential reasons for AAD initiation, candidates for treatment, current medical options, and possible drug-device interactions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom